PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-1.23%
Negative revenue growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
4.03%
Positive gross profit growth while Medical - Pharmaceuticals median is negative. Peter Lynch would see a notable competitive edge in cost or pricing.
16.71%
EBIT growth of 16.71% while Medical - Pharmaceuticals median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
10.30%
Positive operating income growth while Medical - Pharmaceuticals is negative. Peter Lynch would spot a big relative advantage here.
4.09%
Net income growth of 4.09% while Medical - Pharmaceuticals median is zero. Walter Schloss might see potential if moderate gains can keep rising.
4.08%
EPS growth of 4.08% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could compound over time.
4.08%
Diluted EPS growth of 4.08% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could improve over time.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.13%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see an advantage if others are still diluting.
-100.00%
Dividend cuts while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
59.09%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 27.71%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
71.44%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 23.08%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
36.36%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 13.45%. Joel Greenblatt might see a short-term competitive advantage at play.
-100.00%
Negative 10Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
155.81%
Net income/share CAGR of 155.81% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
122.26%
Positive 5Y CAGR while Medical - Pharmaceuticals median is negative. Peter Lynch sees a notable advantage vs. peers struggling to grow net income/share.
61.49%
3Y net income/share CAGR of 61.49% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a small advantage that can be scaled further.
198.97%
Equity/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 79.44% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
124.19%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 28.50%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
57.00%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 17.98%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
-100.00%
Dividend declines over 10 years while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative disadvantage if peers consistently raised payouts.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.00%
AR shrinking while Medical - Pharmaceuticals median grows. Seth Klarman sees potential advantage unless it signals declining demand.
0.29%
Inventory reduction well below Medical - Pharmaceuticals median. Joel Greenblatt might see a sign of superior operational or supply-chain efficiency.
-1.54%
Assets shrink while Medical - Pharmaceuticals median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
4.33%
Positive BV/share change while Medical - Pharmaceuticals median is negative. Peter Lynch finds a strong advantage vs. peers failing to expand equity.
-44.81%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
89.49%
SG&A growth far above Medical - Pharmaceuticals median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.